LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases
The large-scale IMI project will investigate the causes and mechanisms of Atopic Dermatitis and Psoriasis
BALLERUP, Denmark, April 11, 2019 – LEO Pharma, a global leader in medical dermatology and BIOMAP, a EU-funded research project (Biomarkers in Atopic Dermatitis and Psoriasis), today announced that BIOMAP kicks off its activities with the aim of improving the lives of patients affected by the two most common inflammatory skin conditions. Addressing key unmet needs in treating atopic dermatitis and psoriasis by analysing data from more than 50,000 patients, the five-year project will have a broad impact on disease understanding, patient care and future therapies. In addition to LEO Pharma the team comprises 26 academic and five industry partners as well as five patient organisations. The European Innovative Medicines Initiative (IMI) and the participating pharma companies provide EUR 20.8 million funding for the first IMI project in the field of dermatology.
Atopic dermatitis and psoriasis affect more than 300 million people worldwide and are highly variable in terms of onset, severity, progression over time and response to treatment. Resulting in significant morbidity and an increased risk for associated conditions such as arthritis and asthma, inflammatory skin diseases are a huge burden to patients and families, care-givers and healthcare systems. Yet, despite many years of research, there are still significant gaps in the understanding of both conditions.
The renowned clinicians and scientists of BIOMAP, who have now joined forces in a large public-private partnership, will examine the causes and mechanisms of these conditions. By analysing the largest collection of patient data ever and performing advanced molecular investigations at the single cell level and in the tissue context, they aim at identifying biomarkers for variations in disease outcome. Taking advantage of recent technical developments in translational medicine, the project will drive drug discovery and improve direct disease management by combining clinical, genetic and epidemiological expertise with modern molecular analysis techniques and newly-developed tools in bioinformatics. BIOMAP is the first IMI project in the field of dermatology.
“BIOMAP will help us to better understand the relationships between inherited susceptibility, environmental factors, and molecular profiles, as well as the roles of each of these in onset and progression of the diseases”, says Dr Witte Koopmann, industrial co-project lead from LEO Pharma.
Professor Stephan Weidinger, academic coordinator of the consortium and internationally-renowned clinician scientist from the University of Kiel Germany, hopes that “atopic dermatitis and psoriasis will be identified as a series of different diseases rather than just one disease, each with a characteristic molecular ‘signature’.”
“The findings from BIOMAP will drive rapid drug discovery to target causal mechanisms, and will pinpoint biomarkers which can support clinicians to decide who, when and how to intervene”, expects BIOMAP’s academic co-coordinator Professor Catherine Smith from King’s College London.
The voices of patients living with Atopic Dermatitis and Psoriasis will be at the heart of BIOMAP, through the establishment of a Patient Advisory Group. It will ensure that patients’ insights, opinions and wishes are taken into account across all the multiple components of the project.
BIOMAP is funded by the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No. 821511 and in-kind contributions of the participating pharma companies. The Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
The project will officially kick off its activities with a first meeting in London on 10-12 April, 2019.
EURICE – European Research and Project Office GmbH
Dr Verena Peuser
Phone +49 30 374415832
LEO Pharma A/S
Trine Juul Wengel
Tel.: +45 20732037
About LEO Pharma
The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI facilitates collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). For further information: www.imi.europa.eu
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.
For more information, go to: www.linkedin.com/company/leo-pharma or www.leo-pharma.com
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma A/S acquires rights to develop and market brodalumab for moderate-to-severe psoriasis outside of Europe13.8.2019 11:30:00 CEST | Press release
New sub-licensing agreement allows LEO Pharma to help more people around the world with an additional treatment option for psoriasis. August 13th, 2019, Ballerup, Denmark: LEO Pharma A/S, a global leader in medical dermatology, today announced it has acquired the exclusive rights to develop and market brodalumab (marketed as Kyntheum® in the European Union) for the treatment of moderate-to-severe psoriasis outside of Europe through a new sub-licencing agreement with Bausch Health Ireland Limited. The new agreement includes countries with significantly high unmet need, such as Australia, Brazil, Egypt, Mexico, Russia and Saudi Arabia. This complements the ongoing licensing agreement between LEO Pharma A/S and AstraZeneca to develop and market brodalumab for the treatment of moderate-to-severe psoriasis in Europe. To date, LEO Pharma A/S has successfully launched brodalumab in 18 countries. Outside of the EU, Bausch Health Companies Inc. through a licensing agreement with AstraZeneca, ha
LEO Pharma completes the acquisition of Bayer’s pre-scription dermatology business2.7.2019 09:00:00 CEST | Press release
LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO Pharma. The companies first announced the proposed transaction on July 31, 2018 and completed the first step of the acquisition with the closing in the United States on September 4, 2018. Today’s second and final closing covers all other countries.
LEO Pharma udnævner Catherine Mazzacco som ny CEO3.6.2019 09:00:00 CEST | Pressemeddelelse
Ballerup, den 3. juni 2019. LEO Pharma offentliggjorde i dag, at Gitte Aabo efter 27 år i virksomheden – og heraf de seneste 11 som adm. direktør – træder tilbage fra posten som øverste chef den 31. juli 2019. Bestyrelsen har udpeget Catherine Maz-zacco som ny adm. direktør med tiltrædelse 1. august.
LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management10.5.2019 10:27:35 CEST | Press release
Ballerup, Denmark, May 10, 2019 – LEO Pharma A/S, a global leader in medical dermatology, today announced the appointment of Beth-Anne Lang, Vice President and Head of Global Regulatory Affairs and Christine Garrett, Vice President and Head of Global Project Manage-ment. Both will join LEO Pharma on May 13.
New General Manager appointed to lead LEO Pharma across the Nordic region1.5.2019 10:12:37 CEST | Press release
Klaus Abel arrives to take the regional helm of the global medical dermatology leader
New data show that LEO Pharma’s Kyntheum® (brodalumab) sustains PASI 100 scores longer than ustekinumab for people with moderate-to-severe plaque psoriasis25.4.2019 09:12:24 CEST | Press release
Ballerup, Denmark, April 25, 2019: LEO Pharma A/S, a global leader in medical dermatology, today announced that new data presented this week at the 6th Congress of the Skin Inflammation and Psoriasis International Network (SPIN) in Paris demonstrate that more patients with moderate-to-severe psoriasis who received treatment with brodalumab maintained a PASI (Psoriasis Area Severity Index) 100 score for longer than those who were treated with ustekinumab over 52 weeks.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom